Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids.

Prill S, Caddeo A, Baselli G, Jamialahmadi O, Dongiovanni P, Rametta R, Kanebratt KP, Pujia A, Pingitore P, Mancina RM, Lindén D, Whatling C, Janefeldt A, Kozyra M, Ingelman-Sundberg M, Valenti L, Andersson TB, Romeo S.

Sci Rep. 2019 Aug 12;9(1):11585. doi: 10.1038/s41598-019-47737-w.

2.

Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.

Prieto Garcia L, Janzén D, Kanebratt KP, Ericsson H, Lennernäs H, Lundahl A.

Drug Metab Dispos. 2018 Oct;46(10):1420-1433. doi: 10.1124/dmd.118.081364. Epub 2018 Aug 1.

PMID:
30068519
3.

Critical differences in drug metabolic properties of human hepatic cellular models, including primary human hepatocytes, stem cell derived hepatocytes, and hepatoma cell lines.

Kvist AJ, Kanebratt KP, Walentinsson A, Palmgren H, O'Hara M, Björkbom A, Andersson LC, Ahlqvist M, Andersson TB.

Biochem Pharmacol. 2018 Sep;155:124-140. doi: 10.1016/j.bcp.2018.06.026. Epub 2018 Jun 25.

PMID:
29953844
4.

Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Lindmark B, Lundahl A, Kanebratt KP, Andersson TB, Isin EM.

Br J Pharmacol. 2018 Jun;175(11):2116-2129. doi: 10.1111/bph.14203. Epub 2018 Apr 19.

5.

Publisher Correction: Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model.

Bauer S, Wennberg Huldt C, Kanebratt KP, Durieux I, Gunne D, Andersson S, Ewart L, Haynes WG, Maschmeyer I, Winter A, Ämmälä C, Marx U, Andersson TB.

Sci Rep. 2018 Jan 23;8(1):1672. doi: 10.1038/s41598-018-20340-1.

6.

Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model.

Bauer S, Wennberg Huldt C, Kanebratt KP, Durieux I, Gunne D, Andersson S, Ewart L, Haynes WG, Maschmeyer I, Winter A, Ämmälä C, Marx U, Andersson TB.

Sci Rep. 2017 Nov 6;7(1):14620. doi: 10.1038/s41598-017-14815-w. Erratum in: Sci Rep. 2018 Jan 23;8(1):1672.

7.

Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.

Jones BC, Rollison H, Johansson S, Kanebratt KP, Lambert C, Vishwanathan K, Andersson TB.

Drug Metab Dispos. 2017 Jan;45(1):35-41. Epub 2016 Oct 24. Review.

PMID:
27777246
8.

A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 induction.

Mårde Arrhén Y, Nylén H, Lövgren-Sandblom A, Kanebratt KP, Wide K, Diczfalusy U.

Br J Clin Pharmacol. 2013 Jun;75(6):1536-40. doi: 10.1111/bcp.12016.

9.

Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.

Sjögren E, Svanberg P, Kanebratt KP.

Drug Metab Dispos. 2012 Dec;40(12):2273-9. doi: 10.1124/dmd.112.047373. Epub 2012 Aug 31.

PMID:
22942316
10.

The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.

Andersson TB, Kanebratt KP, Kenna JG.

Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):909-20. doi: 10.1517/17425255.2012.685159. Epub 2012 May 8. Review.

PMID:
22568886
11.

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L.

Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.

12.

Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.

Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, Bertilsson L.

Clin Pharmacol Ther. 2008 Nov;84(5):589-94. doi: 10.1038/clpt.2008.132. Epub 2008 Jul 23.

PMID:
18650803
13.

Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies.

Kanebratt KP, Andersson TB.

Drug Metab Dispos. 2008 Jul;36(7):1444-52. doi: 10.1124/dmd.107.020016. Epub 2008 Apr 2.

PMID:
18385292
14.

HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.

Kanebratt KP, Andersson TB.

Drug Metab Dispos. 2008 Jan;36(1):137-45. Epub 2007 Oct 22.

PMID:
17954527

Supplemental Content

Loading ...
Support Center